25 Sep 2026

CRC Research Update — September 25, 2026

Creator: The CRC Digest
Published: 2026-09-25T11:28:32Z

Today's colorectal cancer research highlights

1 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

RESEARCH
KRAS mutations occur in 40% of colorectal cancers and predict resistance to anti-EGFR therapy
A comprehensive review finds KRAS-mutant tumors are associated with increased recurrence risk and reduced survival, including in patients undergoing liver metastasis surgery. (Current Oncology)
TREATMENT
Neoadjuvant therapy plus stent placement reduces stoma rates in obstructive colorectal cancer
A multicenter study of 154 patients found combining neoadjuvant therapy with self-expandable metal stents resulted in significantly lower intraoperative stoma rates compared to stent alone (8.6% vs. 29.0%). (BMC Cancer)
RESEARCH
Ovarian metastases from colorectal cancer show lower chemotherapy response than other sites
Twenty-four retrospective studies comprising 2,705 patients found ovarian metastases demonstrated lower objective chemotherapy response rates than extraovarian metastases and frequently exhibited discordant growth during treatment. (JAMA Oncology)
SCREENING
Portable urine-based biosensor developed for colorectal cancer detection in low-resource settings
Researchers present a low-cost, semi-automated point-of-care platform that measures urinary metabolite biomarkers for CRC triage where colonoscopy access is limited. (Biosensors)

💙 Living with CRC

Survivorship, quality of life, and supportive care

Half of Canadian CRC patients report nutrition status was never or inconsistently discussed during treatment
A national survey of 243 participants found 51.2% of patients had nutritional status discussed, while 24.0% reported it was never addressed. (Current Oncology)

🧬 Biomarker Spotlight

Research by genetic subtype. KRAS, BRAF, MSI-H, HER2, and more

MSI-high CRC with NTRK fusion achieved complete response with FOLFOX-bevacizumab after immunotherapy failure
A 63-year-old woman experienced tumor progression on pembrolizumab but achieved a complete response sustained over three years with second-line chemotherapy. (International Cancer Conference Journal)

This week's research spans biomarker-guided treatment strategies, supportive care gaps, and novel detection platforms.

Get CRC research intelligence delivered weekly, free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest